**AWE-10**

AN INTERNATIONAL SURVEY ON THE DIAGNOSIS AND MANAGEMENT OF SEVERE GASTROINTESTINAL DYSMOTILITY

1Dipesh H Vasant*, 2Loris Pironi, 3Frederico Bozzetti, 4Cristina Cuerda, 5Francisca Joly, 6Darielle Kelly, 7Peter Paine, 8Michael Stau, 9Kingsa Szczepanek, 10André Van Gossum, 11Geert Wante, 12Simon Lal. 1Manchester University Foundation Trust, Manchester, UK; 2University of Bologna, Bologna, Italy; 3University of Milan, Milan, Italy; 4HUGM Nutrition Unit, Madrid, Spain; 5MCI et Assistance Nutrition, Clichy, France; 6Mayo Clinic, Rochester, USA; 7Salford Royal Foundation Trust, UK; 8University of Copenhagen, Copenhagen, Denmark; 9Stanley Dudick’s Memorial Hospital, Skawina, Poland; 10Erasme Hospital, Brussels, Belgium; 11Radboud university medical center, Nijmegen, Netherlands

10.1136/gutjnl-2019-BSGAbstracts.395

**Introduction**

Severe gastrointestinal dysmotility (GID) can be sub-classified into Chronic Intestinal Pseudo-obstruction (CIPO) and Enteric Dysmotility (ED) subtypes. We surveyed current opinions on the diagnosis and management of GID amongst experts from different countries.

**Methods**

An survey questionnaire developed by the European society for Clinical Nutrition and Metabolism (ESPEN) was circulated electronically to members of ESPEN, European Society of Neurogastroenterology and Motility, and United European Gastroenterology. Only participants that completed all required components were included in the analysis.

**Results**

Of 154 included participants, 82% were European, the majority were attending clinicians/professors (85%), based at either national/regional referral centres and/or academic institutions (87%). Almost all (93%) agreed that CIPO and ED should be classed separately. Most (73%), reported increased incidence of GID, with 69% reporting an increase in ED. GID associated with hypermobile Ehlers-Danlos Syndrome was the group with the largest increase in referrals (37%), however this trend was driven by observations from UK participants only (P<0.0001). Almost all clinicians (95%) find diagnosing GID difficult, with 57% finding ED more challenging and 32% find both types equally difficult. GID diagnosis is often delayed (CIPO: by >5 years according to 16%; ED: by >5 years according to 19%). Moreover, by the time of diagnosis, >10% of patients have had inappropriate operations according to 82% of clinicians. Small Bowel Manometry, a test mandated to diagnose ED, is surprisingly never used by 44%, and is only used in >50% cases by 21%. Full thickness biopsies are usually requested from planned/previous resections (33%) or when the diagnosis is unclear (43%), but seldom change medical treatment (12%), nutritional management (16%) and prognosis (25%). Very few treatments are useful for >50% of patients, with antibiotics for SIBO, prucalopride, and psychology felt to be the most useful. Parenteral Nutrition (PN) rarely leads to improvement in symptoms (28%), and is associated with PN dependency at 5-years according to the majority (56%).

**Conclusion**

These data highlight the difficulties with diagnosing and managing GID, even in ‘expert’ hands, and inform the urgent need for international, multidisciplinary, clinical practice guidelines.

---

**PWE-078**

EFFICACY OF PHARMACOLOGICAL THERAPIES IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHOEA: NETWORK META-ANALYSIS

1,2Christopher Black*, 1,2Nicholas Bun, 3Michael Camilleri, 4David Earnest, 4Eamonn Quigley, 5Paul Moayyed, 6Lesley Houghton, 1,2Alexander Ford. 1Leeds Gastroenterology Institute, SIIH, Leeds, UK; 2Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds, UK; 3Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, USA; 4Division of Gastroenterology, The University of Arizona College of Medicine, Tucson, USA; 5Division of Gastroenterology and Hepatology, Houston Methodist Hospital, Houston, USA; 6Gastroenterology Division, McMaster University, Hamilton, Canada

10.1136/gutjnl-2019-BSGAbstracts.396

**Introduction**

Over half of patients with irritable bowel syndrome have either diarrhoea (IBS-D) or a mixed stool pattern (IBS-M). The relative efficacy of licensed pharmacological therapies in IBS-D and IBS-M is unclear in the absence of head-to-head trials. We conducted a network meta-analysis to resolve this uncertainty.

**Methods**

We searched MEDLINE, EMBASE, EMBASE Classic, the Cochrane central register of controlled trials, and clinical-trials.gov through November 2018 to identify randomised controlled trials (RCTs) assessing the efficacy of licensed pharmacological therapies in adults with IBS-D or IBS-M. Trials included in the analysis reported a dichotomous assessment of overall response to therapy, and data were pooled using a random effects model. Efficacy and safety of all pharmacological therapies were reported as a pooled relative risk of remaining symptomatic with 95% confidence intervals (CIs) to summarise the effect of each comparison tested. Treatments were ranked according to their Pscore.

**Results**

We identified 18 eligible RCTs (7 alosetron, 5 ramosetron, 2 rifaximin, 4 eluxadoline), containing 9844 patients. All were superior to placebo for the treatment of IBS-D or IBS-M at 12 weeks, according to the Food and Drug Administration (FDA)-recommended composite endpoint of improvement in both abdominal pain and stool consistency (RR = 0.69; 95% CI 0.60 to 0.80, P-score = 0.97), effect on global symptoms of IBS, and effect on stool consistency. Ramosetron 2.5mg once-daily was ranked first for efficacy, based on the FDA-recommended composite endpoint of improvement in both abdominal pain and stool consistency (90% CI 0.60 to 0.80, P-score = 0.75; 95% CI 0.60 to 0.85, P-score = 0.94). Total numbers of adverse events were significantly greater with alosetron 1mg twice-daily and ramosetron 2.5mg, once-daily, compared with placebo. Rifaximin 550mg three times daily ranked first for safety. Constipation was significantly more common with all drugs, except rifaximin 550mg three times daily.

**Conclusions**

In a network meta-analysis of randomised controlled trials of pharmacological therapies for IBS-D and IBS-M, we found all drugs to be superior to placebo, but alosetron and ramosetron appeared to be the most effective.